COG Sessions

3 – 4 pm Friday, August 18

Nurse-Led Models for Enhancing the Conduct of Children’s Oncology Group Cancer Control Trials (C223)

coglogo1CH  Improvements in survival in pediatric cancer has led to a broadened focus of research that includes symptom prevention and management, patient- and caregiver-reported outcomes, and disease prevention and control. The Children’s Oncology Group (COG) Cancer Control (CCL) Domain conducts independent and embedded clinical trials to identify preventive measures and evaluate interventions to improve patient- and caregiver-reported outcomes and reduce the morbidity of cancer therapy.

Read more...
4:45 –5:45 pm Thursday, August 17

Acute Promyelocytic Leukemia: Current COG treatment for a unique AML subtype (C211)

coglogo

1CH  Acute promyelocytic leukemia (APL), a sub-classification of acute myeloid leukemia (AML), is characterized by the t(15,17) gene mutation. Though survival rates for pediatric patients with newly diagnosed AML generally remain suboptimal, changes in treatment for the APL subtype, including the addition of arsenic trioxide (ATO), have improved survival rates to more than 90%.

Read more...
3:30 – 4:30 pm Thursday, August 17

Acute Lymphoblastic Leukemia: Current COG Trials for T Cell, Ph+, and Ph-Like ALL (C205)

coglogo1CH  Although the current overall 5-year survival rate for acute lymphoblastic leukemia (ALL) is more than 85%, patients with some subsets of ALL continue to have poorer event-free survival (EFS). T-Cell ALL, Philadelphia chromosome positive (Ph+) and Ph-like ALL subtypes have suboptimal EFS rates and are the focus of new treatment approaches within the Children’s Oncology Group.

Read more...